Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit?

Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit?

Blog Article

Dasatinib is a tyrosine kinase inhibitor used for treatment of some specific types of leukaemia.The development of pleural effusion is a known adverse slate vcc effect of dasatinib and chylothorax is exceptional.No case has been reported beyond 5 years of treatment and extensive search for an alternative diagnosis is currently suggested in craggy range sauvignon blanc 2022 such scenario.The underlying mechanism is not currently clear.

We describe a woman on dasatinib treatment for more than 10 years who developed chylothorax.Drug withdrawal resolved the chylous pleural effusion.We were able to find 14 additional cases of dasatinib-related chylothorax reported up until now.